New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:55 EDTBIIBBiogen's TECFIDERA approved in the European Union
Biogen announced that TECFIDERA has been approved by the European Commission as a first-line oral treatment for people with relapsing-remitting multiple sclerosis. Biogen will begin to introduce TECFIDERA in initial European Union countries in the coming weeks. The EC approval is based on a clinical development program that included two global Phase 3 clinical trials, DEFINE and CONFIRM, as well as an ongoing extension study, ENDORSE, in which some patients have been followed for up to six and a half years. TECFIDERA has been clinically shown to "significantly" reduce important measures of disease activity, including relapses and the development of brain lesions, as well as to slow disability progression, while demonstrating a favorable safety and tolerability profile.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
15:26 EDTBIIBBiogen January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
January 15, 2015
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information
January 14, 2015
07:05 EDTBIIBIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use